Long-term immune protection against HBV: associated factors and determinants

Figures & data

Table 1. Variables associated with persistence of protective Hepatitis B surface antibody titers

	Anti-HBs≥10mIU/mL			Anti-HBs <10mIU/mL
	Vaccinated at infancy	Vaccinated at age 12 years	P value	Vaccinated at infancy	Vaccinated at age 12 years	P value
N (%)	118 (59.9)	121 (83.5)	<0.001^a	79 (40.1)	24 (16.5)	<0.001^a
Sex
Male, n (%)	41 (12)	42 (12.3)	0.995^a	33 (9.6)	10 (2.9)	0.993^a
Female, n (%)	77 (22.5)	79 (23.1)		46 (13.5)	14 (4.1)
Age in year (mean±SD)	23.3 ± 2.3	30.1 ± 2.8	<0.001^b	22.8 ± 2.0	29.9 ± 2.0	<0.001^b
Years since HBV vaccination (mean±SD)	22.4 ± 2.2	18.4 ± 2.9	<0.001^b	21.8 ± 1.6	18 ± 2.1	<0.001^b
University course
Healthcare profession school, n (%)	85 (24.9)	7 (2.1)	<0.001^a	67 (19.6)	1 (0.7)	<0.001^a
Postgraduate students, n (%)	33 (9.6)	114 (33.3)		12 (3.5)	23 (6.7)
GMC of anti-HBs (mIU/mL)	53.7	191.1	0.0025^b	2.5	2.1	0.8653^b

^aPearson chi-squared test for categorical variables.

^bMann–Whitney U Test.

Table 2. Multivariable logistic regression model including variables associated with Hepatitis B surface antibody titers ≥ 10 mIU/mL

	P value	OR	C.I.
University course, n (%)
Healthcare profession school
Postgraduate medical school	0.008	2.76	1.31–5.83
Vaccination period
Vaccinated at infancy
Vaccinated at age 12 years	0.019	10.27	1.47–71.81
Sex
Male
Female	0.356	0.79	0.48–1.30
Age^a	0.082	0.56	0.29–1.08
Years since HBV vaccination	0.096	1.17	0.97–1.42

^aas class of age on 4-points ordinal scale.